Aiming to evaluate the suitability of the established bioluminescent canine DLBCL xenograft model for monitoring tumor progression and therapeutic responsiveness, we conducted an in vivo therapeutic study using panobinostat, a HDAC inhibitor. The gene discussed is HDAC9; the disease is diffuse large B-cell lymphoma.